表紙
市場調査レポート

神経調節の世界市場 〜2020年:技術別(脳深部刺激、脊椎刺激、経頭蓋磁気刺激)、用途別(鬱病、パーキンソン病、耳鳴り、アルツハイマー病、てんかん、虚血、肥満)の動向と予測

Neuromodulation Market by Technology (Deep Brain Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation) & by Application (Depression, Parkinson's, Tinnitus, Alzheimer's, Epilepsy, Ischemia, Obesity) - Trends & Global Forecast to 2020

発行 MarketsandMarkets 商品コード 259725
出版日 ページ情報 英文 159 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
神経調節の世界市場 〜2020年:技術別(脳深部刺激、脊椎刺激、経頭蓋磁気刺激)、用途別(鬱病、パーキンソン病、耳鳴り、アルツハイマー病、てんかん、虚血、肥満)の動向と予測 Neuromodulation Market by Technology (Deep Brain Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation) & by Application (Depression, Parkinson's, Tinnitus, Alzheimer's, Epilepsy, Ischemia, Obesity) - Trends & Global Forecast to 2020
出版日: 2015年07月02日 ページ情報: 英文 159 Pages
概要

世界の医療業界では、慢性および難治性の疾患を副作用を押さえながら治療できる低侵襲性治療に注目しています。これにより神経調節市場は大きく拡大しています。北米が最大のシェアを有し、これに欧州、アジア太平洋地域がつづきます。類似の製品を有する大小さまざまな規模の企業が参入しており、世界の神経調節市場は競争が激化しています。

当レポートでは、世界の神経調節市場について詳細に分析し、製品別、用途別、および地域別の動向、および主要ベンダーのプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 プレミアムインサイト

第5章 市場概要

  • イントロダクション
  • 市場セグメンテーション
  • 市場動向
    • 促進因子
      • 神経疾患の罹患率上昇が市場の成長を牽引
      • 高齢者のこれまでにない増加が市場成長を加速
      • 標的とする用途と新たな適応が成長を刺激すると予測される
      • 投資と資金調達
    • 阻害因子
      • 好ましくない償還シナリオが市場の成長を阻害
      • 教育を受けた専門家の不足が市場の成長を阻害
    • 機会
      • 新興市場における拡大
      • 強固な製品パイプライン

第6章 製品別神経調節市場

  • イントロダクション
  • 体内神経調節
  • 体外神経調節

第7章 用途別神経調節市場

  • イントロダクション
  • 脊椎刺激
  • 脳深部刺激
  • 仙骨神経刺激
  • 迷走神経刺激
  • 胃電気刺激
  • 経皮的電気神経刺激
  • 経頭蓋磁気刺激
  • 呼吸器電気刺激

第8章 地域別市場

  • イントロダクション
  • 北米
  • 欧州
  • アジア
  • その他

第9章 競合環境

  • 概要
  • 市場シェア分析
  • MEDTRONIC, INC.
  • BOSTON SCIENTIFIC CORPORATION
  • ST. JUDE MEDICAL, INC.
  • 競合シナリオ

第10章 企業プロファイル

  • イントロダクション
  • MEDTRONIC, INC.
  • BOSTON SCIENTIFIC CORPORATION
  • ST. JUDE MEDICAL, INC.
  • CYBERONICS, INC.
  • NEVRO CORPORATION
  • NEUROSIGMA, INC.
  • NEUROPACE, INC.
  • BIOCONTROL MEDICAL
  • SYNAPSE BIOMEDICAL, INC.
  • NEURONETICS, INC.

第11章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BT 3571

Over the years, the global healthcare industry has witnessed a paradigm shift, and is now increasingly focused on minimally invasive therapies that not only treats a wide range of chronic and refractory disorders but also have fewer side effects. The demand for neuromodulation has increased significantly, because of patients' preference for minimally invasive surgeries. Moreover, these therapies are reversible, which allows physicians to cease treatment, as and when required by removing the stimulating devices.

Based on technology, the internal neuromodulation segment is expected to be the largest and fastest-growing component segment in 2015. In internal neuromodulation category, spinal cord stimulation segment is expected to dominate the neuromodulation market in 2015. However, the deep brain stimulation segment is expected to grow at the highest CAGR from 2015 to 2020. In the external neuromodulation category, the transcutaneous electrical nerve stimulation segment is expected to be the largest segment in the neuromodulation market. However, the transcranial magnetic stimulation segment has registered the highest CAGR during the forecast period.

North America is expected to account for the largest share of the neuromodulation market, followed by Europe, Asia-Pacific, and rest of the world (RoW) in 2015. In the coming years, the neuromodulation market is expected to witness the highest growth rate in the Asian region, with emphasis on India, China, and Japan. These countries are expected to increase revenues for the manufacturers of equipment and devices involved in neuromodulation.

The global neuromodulation market witnesses high-competitive intensity as there are several big and small firms with similar product offerings. These companies adopt various strategies (agreements, partnerships, mergers, collaborations, acquisitions, new product launches, market development, geographical expansions, and acquisitions) to increase their market shares and establish a strong foothold in the global neuromodulation market.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps companies, garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by top players in the neuromodulation market. The report analyzes the neuromodulation market by technology and application
  • Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the neuromodulation market
  • Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various neuromodulation technologies across regions
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the neuromodulation market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the neuromodulation market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
    • 2.2.2. PRIMARY RESEARCH
      • 2.2.2.1. Key data from primary sources
      • 2.2.2.2. Key Insights from primary sources
      • 2.2.2.3. Key industry insights
    • 2.2.3. MARKET SIZE ESTIMATION METHODOLOGY
    • 2.2.4. RESEARCH DESIGN
    • 2.2.5. MARKET DATA VALIDATION AND TRIANGULATION
    • 2.2.6. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. GLOBAL NEUROMODULATION MARKET OVERVIEW
  • 4.2. GLOBAL NEUROMODULATION MARKET, BY TYPE
  • 4.3. GEOGRAPHIC ANALYSIS OF THE DEEP BRAIN STIMULATION MARKET, BY APPLICATION
  • 4.4. INTERNAL NEUROMODULATION MARKET, BY MODALITY
  • 4.5. GEOGRAPHICAL SNAPSHOT OF THE NEUROMODULATION MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. Rising prevalence of neurological disorders to spur market growth
      • 5.3.1.2. Unprecedented increase in the aging population to fuel market growth
      • 5.3.1.3. Expanded target applications and new indications are expected to stimulate the growth of neuromodulation devices
      • 5.3.1.4. Investments and funds - an impetus for market growth
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. Unfavorable reimbursement scenario hinders market growth
      • 5.3.2.2. Lack of trained professionals likely to hamper market growth
    • 5.3.3. OPPORTUNITIES
      • 5.3.3.1. Expansion in Emerging Economies
      • 5.3.3.2. Strong product pipeline to propel the market

6. GLOBAL NEUROMODULATION MARKET, BY TECHNOLOGY

  • 6.1. INTRODUCTION
  • 6.2. INTERNAL NEUROMODULATION
    • 6.2.1. SPINAL CORD STIMULATION (SCS)
    • 6.2.2. DEEP BRAIN STIMULATION (DBS)
    • 6.2.3. VAGUS NERVE STIMULATION (VNS)
    • 6.2.4. SACRAL NERVE STIMULATION (SNS)
    • 6.2.5. GASTRIC ELECTRICAL STIMULATION (GES)
  • 6.3. EXTERNAL NEUROMODULATION (NON-INVASIVE)
    • 6.3.1. TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
    • 6.3.2. TRANSCRANIAL MAGNETIC STIMULATION (TMS)
    • 6.3.3. RESPIRATORY ELECTRICAL STIMULATION (RES)

7. GLOBAL NEUROMODULATION MARKET, BY APPLICATION

  • 7.1. INTRODUCTION
  • 7.2. SPINAL CORD STIMULATION (SCS) MARKET, BY APPLICATION
    • 7.2.1. FAILED BACK SYNDROME (FBSS)
    • 7.2.2. CHRONIC PAIN
    • 7.2.3. ISCHEMIA
  • 7.3. DEEP BRAIN STIMULATION (DBS) MARKET, BY APPLICATION
    • 7.3.1. PARKINSON'S DISEASE
    • 7.3.2. TREMOR
    • 7.3.3. DEPRESSION
    • 7.3.4. OTHER DBS APPLICATIONS
  • 7.4. SACRAL NERVE STIMULATION MARKET, BY APPLICATION
    • 7.4.1. URINE INCONTINENCE
    • 7.4.2. FECAL INCONTINENCE
  • 7.5. VAGUS NERVE STIMULATION MARKET, BY APPLICATION
    • 7.5.1. EPILEPSY
    • 7.5.2. OTHER VNS APPLICATIONS
  • 7.6. GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION
    • 7.6.1. GASTROPARESIS
    • 7.6.2. OBESITY
  • 7.7. TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION
    • 7.7.1. TREATMENT RESISTANT DEPRESSION
    • 7.7.2. OTHER TENS APPLICATIONS
  • 7.8. REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION
    • 7.8.1. DEPRESSION
    • 7.8.2. MIGRAINE HEADACHE
  • 7.9. RESPIRATORY ELECTRICAL STIMULATION MARKET, BY APPLICATION
    • 7.9.1. SPINAL CORD INJURY

8. NEUROMODULATION MARKET, BY REGION

  • 8.1. INTRODUCTION
  • 8.2. NORTH AMERICA
    • 8.2.1. U.S.
      • 8.2.1.1. Rising prevalence of chronic diseases in the U.S.
      • 8.2.1.2. Increasing aging population in the U.S.
      • 8.2.1.3. Increasing Lyme disease cases in the U.S.
      • 8.2.1.4. Conferences & annual meetings to increase exposure of neuromodulation
    • 8.2.2. CANADA
      • 8.2.2.1. Increasing incidence of Lyme disease in Canada
      • 8.2.2.2. Increasing incidences of cancer and diabetes
  • 8.3. EUROPE
    • 8.3.1. RAPIDLY AGING POPULATION IN EUROPE
      • 8.3.1.1. Conferences & annual meetings to increase exposure to Neuromodulation in the European market
    • 8.3.2. GERMANY
      • 8.3.2.1. Rising prevalence of Parkinson's disease in Germany
    • 8.3.3. U.K.
      • 8.3.3.1. Rising Prevalence of Diabetes in the U.K.
      • 8.3.3.2. Rise in CVD prevalence in the U.K.
    • 8.3.4. FRANCE
      • 8.3.4.1. Rising incidences of Alzheimer's disease and dementia
    • 8.3.5. REST OF EUROPE
      • 8.3.5.1. High diabetes prevalence in Russia, Turkey, Poland, Romania, and Ukraine
  • 8.4. ASIA-PACIFIC
    • 8.4.1. JAPAN
      • 8.4.1.1. Rising adoption of neurostimulation
    • 8.4.2. CHINA
      • 8.4.2.1. High diabetes incidences and rapidly aging population
    • 8.4.3. INDIA
      • 8.4.3.1. Increasing geriatric population & high diabetes incidence
      • 8.4.3.2. Conferences on neuromodulation & pain management in India
    • 8.4.4. REST OF ASIA-PACIFIC (ROAPAC)
      • 8.4.4.1. Increasing prevalence Of Parkinson's disease in Singapore
      • 8.4.4.2. Conferences on neuromodulation in Australia
  • 8.5. REST OF THE WORLD
    • 8.5.1. INCREASING INCIDENCES OF CANCER IN LATIN AMERICA
    • 8.5.2. RISE IN AGING POPULATION & PREVALENCE OF DIABETES

9. COMPETITIVE LANDSCAPE

  • 9.1. OVERVIEW
  • 9.2. MARKET SHARE ANALYSIS, BY KEY PLAYER
    • 9.2.1. INTRODUCTION
  • 9.3. MEDTRONIC, INC.
  • 9.4. BOSTON SCIENTIFIC CORPORATION
  • 9.5. ST. JUDE MEDICAL, INC.
  • 9.6. COMPETITIVE SCENARIO
    • 9.6.1. MARKET DEVELOPMENT
    • 9.6.2. AGREEMENTS, COLLABORATIONS, MERGERS, AND PARTNERSHIPS
    • 9.6.3. NEW PRODUCT LAUNCHES
    • 9.6.4. ACQUISITIONS
    • 9.6.5. EXPANSION

10. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 10.1. INTRODUCTION
  • 10.2. MEDTRONIC, INC.
  • 10.3. BOSTON SCIENTIFIC CORPORATION
  • 10.4. ST. JUDE MEDICAL, INC.
  • 10.5. CYBERONICS, INC.
  • 10.6. NEVRO CORPORATION
  • 10.7. NEUROSIGMA, INC.
  • 10.8. NEUROPACE, INC.
  • 10.9. BIOCONTROL MEDICAL
  • 10.10. SYNAPSE BIOMEDICAL, INC.
  • 10.11. NEURONETICS, INC.

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

11. APPENDIX

  • 11.1. DISCUSSION GUIDE
  • 11.2. COMPANY DEVELOPMENTS (2012-2015)
    • 11.2.1. MEDTRONIC, INC.
    • 11.2.2. BOSTON SCIENTIFIC CORPORATION
    • 11.2.3. ST JUDE MEDICAL, INC.
    • 11.2.4. NEUROSIGMA, INC.
  • 11.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 11.4. AVAILABLE CUSTOMIZATIONS
  • 11.5. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: INCREASING INCIDENCE OF NEUROLOGICAL DISORDERS IS PROPELLING THE GROWTH OF THE GLOBAL NEUROMODULATION MARKET
  • TABLE 2: UNFAVOURABLE REIMBURSEMENT STRUCTURE IS RESTRAINING THE GROWTH OF THE GLOBAL NEUROMODULATION MARKET
  • TABLE 3: EXPANSION IN EMERGING MARKETS HAS A HUGE POTENTIAL FOR GROWTH IN THE GLOBAL NEUROMODULATION MARKET
  • TABLE 4: GLOBAL NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 5: INTERNAL NEUROMODULATION MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 6: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 7: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 (UNITS)
  • TABLE 8: SPINAL CORD STIMULATION MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 9: SPINAL CORD STIMULATION MARKET SIZE, 2013-2020 (UNITS)
  • TABLE 10: DEEP BRAIN STIMULATION MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 11: DEEP BRAIN STIMULATION MARKET SIZE, BY REGION, 2013-2020 (UNITS)
  • TABLE 12: VAGUS NERVE STIMULATION MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 13: VAGUS NERVE STIMULATION MARKET SIZE, BY REGION, 2013-2020 (UNITS)
  • TABLE 14: SACRAL NERVE STIMULATION MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 15: SACRAL NERVE STIMULATION MARKET SIZE, BY REGION, 2013-2020 (UNITS)
  • TABLE 16: GASTRIC ELECTRICAL STIMULATION MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 17: GASTRIC ELECTRICAL STIMULATION MARKET SIZE, BY REGION, 2013-2020 (UNITS)
  • TABLE 18: EXTERNAL NEUROMODULATION MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 19: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 20: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 (UNITS)
  • TABLE 21: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 22: GASTRIC ELECTRICAL STIMULATION MARKET SIZE, BY REGION, 2013-2020 (UNITS)
  • TABLE 23: TRANSCRANIAL MAGNETIC STIMULATION MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 24: TRANSCRANIAL MAGNETIC STIMULATION MARKET SIZE, BY REGION, 2013-2020 (UNITS)
  • TABLE 25: RESPIRATORY ELECTRICAL STIMULATION MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 26: RESPIRATORY ELECTRICAL STIMULATION MARKET SIZE, BY REGION, 2013-2020 (UNITS)
  • TABLE 27: GLOBAL SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 28: GLOBAL DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 29: GLOBAL SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 30: GLOBAL VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 31: GLOBAL GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 32: GLOBAL TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 33: GLOBAL TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 34: NEUROMODULATION MARKET SIZE, BY REGION, 2013-2020($MILLION)
  • TABLE 35: NORTH AMERICA: NEUROMODULATION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 36: NORTH AMERICA: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 37: NORTH AMERICA: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 38: NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 39: U.S.: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 40: U.S.: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 41: U.S. : EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 42: CANADA: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 43: CANADA : INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 44: CANADA: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 45: EUROPE: NEUROMODULATION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 46: EUROPE: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 47: EUROPE: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 48: EUROPE: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 49: GERMANY: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 50: GERMANY: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 51: GERMANY: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 52: U.K.: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 53: U.K.: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 54: U.K.: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 55: FRANCE: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 56: FRANCE: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 57: FRANCE: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 58: REST OF EUROPE: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 59: REST OF EUROPE: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 60: REST OF EUROPE: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 61: ASIA-PACIFIC: NEUROMODULATION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 62: ASIA-PACIFIC: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 63: ASIA-PACIFIC: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 64: ASIA-PACIFIC: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 65: JAPAN: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 66: JAPAN: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 67: JAPAN: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 68: CHINA: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 69: CHINA: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 70: CHINA: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 71: INDIA: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 72: INDIA: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 73: INDIA: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 74: ROAPAC: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 75: ROAPAC: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 76: ROAPAC: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 77: REST OF THE WORLD: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 78: REST OF THE WORLD: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 79: REST OF THE WORLD: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION)
  • TABLE 80: RECENT DEVELOPMENTS, 2012-2014
  • TABLE 81: RECENT DEVELOPMENTS, 2012-2014
  • TABLE 82: RECENT DEVELOPMENTS, 2012-2014
  • TABLE 83: RECENT DEVELOPMENTS, 2012-2014
  • TABLE 84: RECENT DEVELOPMENTS, 2012-2014

LIST OF FIGURES

  • FIGURE 1: NEUROMODULATION MARKET SEGMENTATION
  • FIGURE 2: GLOBAL NEUROMODULATION MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 3: BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 5: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: INTERNAL NEUROMODULATION SEGMENT TO WITNESS THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 8: DEEP BRAIN STIMULATION TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 9: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION IS EXPECTED TO COMMAND THE LARGEST SHARE IN 2015
  • FIGURE 10: PARKINSON'S DISEASE IS EXPECTED TO COMMAND THE LARGEST SHARE IN 2015
  • FIGURE 11: ASIA-PACIFIC SLATED TO WITNESS THE HIGHEST GROWTH IN THE NEUROMODULATION MARKET DURING THE FORECAST PERIOD
  • FIGURE 12: ATTRACTIVE OPPORTUNITIES IN THE NEUROMODULATION MARKET
  • FIGURE 13: INTERNAL MODULATION TECHNOLOGY TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 14: NORTH AMERICA TO DOMINATE THE NEUROMODULATION MARKET
  • FIGURE 15: DEEP BRAIN STIMULATION SEGMENT TO WITNESS HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 16: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH RATE FROM 2015 TO 2020
  • FIGURE 17: DRIVERS, RESTRAINTS & OPPORTUNITIES
  • FIGURE 18: GLOBAL NEUROMODULATION MARKET, BY TYPE
  • FIGURE 19: INTERNAL NEUROMODULATION SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 20: ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 21: DEEP BRAIN STIMULATION TO GROWTH AT A HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 22: ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 23: TRANSCRANIAL MAGNETIC STIMULATION TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 24: GLOBAL INTERNAL NEUROMODULATION MARKET, BY APPLICATION
  • FIGURE 25: GLOBAL EXTERNAL NEUROMODULATION MARKET, BY APPLICATION
  • FIGURE 26: NORTH AMERICA IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE GLOBAL NEUROMODULATION MARKET IN 2015
  • FIGURE 27: U.S. TO WITNESS THE HIGHEST GROWTH IN THE GLOBAL NEUROMODULATION MARKET IN NORTH AMERICA (2015)
  • FIGURE 28: GERMANY TO WITNESS THE HIGHEST GROWTH IN THE GLOBAL NEUROMODULATION MARKET IN EUROPE (2015)
  • FIGURE 29: ASIA-PACIFIC, THE FASTEST-GROWING SEGMENT IN THE GLOBAL MARKET
  • FIGURE 30: ROW EXPECTED TO GROW AT A CAGR DURING 2015 TO 2020
  • FIGURE 31: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014
  • FIGURE 32: STRATEGIES ADOPTED BY KEY PLAYERS OVER THE LAST FOUR YEARS (2012-2015)
  • FIGURE 33: BATTLE FOR MARKET SHARE: MARKET DEVELPOMENT WAS THE KEY STRATEGY
  • FIGURE 34: GEOGRAPHICAL REVENUE MIX OF TOP PLAYERS
  • FIGURE 35: MEDTRONIC, INC.: COMPANY SNAPSHOT
  • FIGURE 36: BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • FIGURE 37: ST JUDE MEDICAL, INC.: COMPANY SNAPSHOT
  • FIGURE 38: CYBERONICS, INC.: COMPANY SNAPSHOT
  • FIGURE 39: NEVRO CORPORATION: COMPANY SNAPSHOT
Back to Top